FLUPENTHIXOL DECANOATE IN CRACK COCAINE SMOKING

可卡因滥用通常会产生严重的可卡因依赖，即 对现有的药物和门诊精神疗法难以奏效 治疗。在一项开放的试点试验中，我们评估了一个仓库的效果 需要很少给药的xanthene，flupenthixol decanoate， 因为吸食可卡因。10名预后不佳的门诊“可卡因” 吸烟者在一种开放标签，开放的... 结束了审判。氟苯硫辛酯耐受性良好，似乎对 显著并迅速地减少可卡因的渴望和使用，产生260%的 在这些受试者中，他们的平均水平比之前的治疗增加了1% 治疗中保留的时间。这个应用程序提出了一个双盲 氟苯硫辛酯的临床试验与目前口服的比较 药物治疗，地塞帕明。90名滥用可卡因的人将被 在随机治疗的临床试验中进行治疗，比较三种方法 在常规治疗的基础上增加对比药理治疗 心理治疗：(A)安慰剂地昔帕明加安慰剂肌肉注射氟苯硫醇 (B)地昔帕明加安慰剂I.M.Flupenthixol 低密度脂蛋白(n=30)。结果将是多维的。12个月后- 将执行UP评估以评估耐用性和/或 治疗效果出现延迟。

"Crack" cocaine abuse often produces severe cocaine dependence that is refractory to available pharmacological and outpatient psychotherapeutic treatments. In an open pilot trial, we evaluated the efficacy o a depot xanthene requiring infrequent IM administration, flupenthixol decanoate, for cocaine withdrawal. Ten poor prognosis, outpatient "crack" cocain smokers were administered flupenthixol decanoate in an open-label, open- ended trial. flupenthixol decanoate was well tolerated, and appeared to markedly and rapidly decrease cocaine craving and use, producing a 260% per cent increase over prior treatment in these subjects in their average time retained in treatment. This application proposes a double-blind flupenthixol decanoate trial with a comparison to a current oral pharmacotherapy, desipramine. Ninety "crack" cocain abusers will be treated in a clinical trial with randomized treatment comparing three contrasting pharmacological treatments added to conventional psychotherapy: (a) Placebo Desipramine plus Placebo I.M. Flupenthixol de==Decanoate (n=30) (b) Desipramine plus Placebo I. M. Flupenthixol Decanoate (n=30). Outcomes will be multidimensional. Twelve month follow- up evaluations will be performed to evaluate the durability and/or delayed emergence of treatment effects.